UA73100C2 - Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist - Google Patents

Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist Download PDF

Info

Publication number: UA73100C2
Authority: UA; Ukraine
Prior art keywords: mgr; ttr; aia; rne; niz
Prior art date: 1998-11-16

Application number

UA2001064044A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Zentaris Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-16

Filing date

1999-11-11

Publication date

2005-06-15

1999-11-11 Application filed by Zentaris Ag filed Critical Zentaris Ag

2005-06-15 Publication of UA73100C2 publication Critical patent/UA73100C2/uk

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 61
206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
238000000034 method Methods 0.000 title claims abstract description 17
102000018997 Growth Hormone Human genes 0.000 title claims abstract description 16
108010051696 Growth Hormone Proteins 0.000 title claims abstract description 16
239000005557 antagonist Substances 0.000 title claims abstract description 16
239000000122 growth hormone Substances 0.000 title claims abstract description 16
230000035755 proliferation Effects 0.000 title claims abstract description 5
230000002401 inhibitory effect Effects 0.000 title claims description 3
201000011510 cancer Diseases 0.000 title description 4
210000001685 thyroid gland Anatomy 0.000 claims abstract description 6
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 3
210000001519 tissue Anatomy 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 8
102100033367 Appetite-regulating hormone Human genes 0.000 claims description 5
230000002285 radioactive effect Effects 0.000 claims description 5
108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 4
210000005075 mammary gland Anatomy 0.000 claims description 4
239000003550 marker Substances 0.000 claims description 3
210000000496 pancreas Anatomy 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 2
-1 bicyclic compound Chemical class 0.000 claims 1
201000006385 lung benign neoplasm Diseases 0.000 claims 1
231100000590 oncogenic Toxicity 0.000 claims 1
230000002246 oncogenic effect Effects 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
241000124008 Mammalia Species 0.000 abstract description 5
210000004072 lung Anatomy 0.000 abstract description 5
206010006187 Breast cancer Diseases 0.000 abstract description 4
206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 2
208000024770 Thyroid neoplasm Diseases 0.000 abstract description 2
208000037841 lung tumor Diseases 0.000 abstract description 2
CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 abstract 1
208000013076 thyroid tumor Diseases 0.000 abstract 1
231100000588 tumorigenic Toxicity 0.000 abstract 1
230000000381 tumorigenic effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 22
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 13
108010070965 hexarelin Proteins 0.000 description 13
229920000642 polymer Polymers 0.000 description 11
230000027455 binding Effects 0.000 description 9
230000000694 effects Effects 0.000 description 8
206010058467 Lung neoplasm malignant Diseases 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
230000002124 endocrine Effects 0.000 description 5
201000005296 lung carcinoma Diseases 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
230000009870 specific binding Effects 0.000 description 5
229940104230 thymidine Drugs 0.000 description 5
102000005157 Somatostatin Human genes 0.000 description 4
108010056088 Somatostatin Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
230000001028 anti-proliverative effect Effects 0.000 description 4
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 4
229960000553 somatostatin Drugs 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000013068 control sample Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000003446 ligand Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000003325 follicular Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010082883 EP80317 Proteins 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000700159 Rattus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000012445 acidic reagent Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
201000011523 endocrine gland cancer Diseases 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229940050411 fumarate Drugs 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000012333 histopathological diagnosis Methods 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
102000045360 human SDHB Human genes 0.000 description 1
229960002050 hydrofluoric acid Drugs 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000030776 invasive breast carcinoma Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
MDKCOSRPPDDOPZ-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepin-2-amine Chemical compound N1=CC=CC=C2C3=NC(N)=CC3=CC=C21 MDKCOSRPPDDOPZ-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
229940114926 stearate Drugs 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Zoology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

UA2001064044A 1998-11-16 1999-11-11 Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist UA73100C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/192,406 US6124263A (en)	1998-11-16	1998-11-16	Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
PCT/EP1999/008662 WO2000029011A1 (en)	1998-11-16	1999-11-11	Treatment of tumors by administration of growth hormone releasing compounds and their antagonists

Publications (1)

Publication Number	Publication Date
UA73100C2 true UA73100C2 (en)	2005-06-15

Family

ID=22709509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001064044A UA73100C2 (en)	1998-11-16	1999-11-11	Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist

Country Status (30)

Country	Link
US (1)	US6124263A (de)
EP (1)	EP1131083B1 (de)
JP (1)	JP2002529512A (de)
KR (1)	KR100704138B1 (de)
CN (3)	CN1200726C (de)
AR (1)	AR021286A1 (de)
AT (1)	ATE258062T1 (de)
BG (1)	BG105572A (de)
BR (1)	BR9915390A (de)
CA (1)	CA2350914A1 (de)
CO (1)	CO5140111A1 (de)
CZ (1)	CZ20011577A3 (de)
DE (1)	DE69914365T2 (de)
DK (1)	DK1131083T3 (de)
ES (1)	ES2212650T3 (de)
HK (1)	HK1040934A1 (de)
HU (1)	HUP0104374A3 (de)
IL (1)	IL142858A0 (de)
MX (1)	MXPA01004689A (de)
NO (1)	NO20012367L (de)
NZ (1)	NZ511280A (de)
PL (1)	PL347659A1 (de)
PT (1)	PT1131083E (de)
RU (1)	RU2240133C2 (de)
SK (1)	SK6352001A3 (de)
TR (1)	TR200101350T2 (de)
TW (2)	TWI237565B (de)
UA (1)	UA73100C2 (de)
WO (1)	WO2000029011A1 (de)
ZA (1)	ZA200103182B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6211156B1 (en) *	1999-11-10	2001-04-03	Asta Medica A.G.	Peptides for treatment of erectile dysfunction
CU23157A1 (es) *	2001-01-03	2006-07-18	Ct Ingenieria Genetica Biotech	COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
DE10112882A1 (de) *	2001-03-15	2002-09-19	Max Delbrueck Centrum	Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren
US20040157227A1 (en) *	2001-05-10	2004-08-12	Chopin Lisa Kerstin	Reproductive cancer diagnosis and therapy
EP1312363A1 (de) *	2001-09-28	2003-05-21	Pfizer Products Inc.	Behandlungsverfahren und kits bestehend aus Wachstumshormonsekretionsförderern
TWI331922B (en) *	2002-08-09	2010-10-21	Ipsen Pharma Sas	Growth hormone releasing peptides
WO2005027913A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US20050164952A1 (en) *	2004-01-23	2005-07-28	Vital Pharmaceuticals, Inc.	Delivery system for growth hormone releasing peptides
EP2021015A2 (de) *	2006-04-28	2009-02-11	The Administrators Of The Tulane Educational Fund	Ghrelin/ghrp/ghsr-antagonisten und ihre verwendung
US8299022B2 (en)	2006-09-27	2012-10-30	Ipsen Pharma S.A.S.	Analogs of ghrelin substituted at the N-terminal
CA2677813A1 (en)	2007-02-13	2008-08-21	Helsinn Therapeutics (U.S.), Inc.	Method of treating cell proliferative disorders using growth hormone secretagogues
WO2010118309A2 (en) *	2009-04-10	2010-10-14	Board Of Regents, The University Of Texas System	Inhibitors of stat3 and uses thereof
US9724381B2 (en)	2009-05-12	2017-08-08	The Administrators Of The Tulane Educational Fund	Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
IT1399610B1 (it) *	2010-01-28	2013-04-26	Univ Milano Bicocca	Uso di agonisti e antagonisti dei recettori per i growth hormone secretagogues per la prevenzione e il trattamento di convulsioni ed epilessia
CA3129405A1 (en)	2019-02-08	2020-08-13	United States Government As Represented By The Department Of Veterans Affairs	Growth hormone-releasing hormone antagonists and uses thereof
CN114126653B (zh) *	2019-07-18	2024-02-20	迈阿密大学	用于治疗结节病的方法的ghrh拮抗剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2053250A1 (en) *	1989-04-26	1990-10-27	David H. Coy	Linear somatostatin analogs
IT1240643B (it) *	1990-05-11	1993-12-17	Mediolanum Farmaceutici Spa	Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
GB2244063A (en) *	1990-05-15	1991-11-20	Exxon Research Engineering Co	Grease composition containing inorganic compounds
RO117259B1 (ro) *	1993-08-09	2001-12-28	Biomeasure Inc.	Derivaţi peptidici, terapeutici
US5550212A (en) *	1993-12-17	1996-08-27	The Administrators Of The Tulane Educational Fund	Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5807985A (en) *	1996-06-11	1998-09-15	Deghenghi; Romano	Oligopeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone
US6063796A (en) *	1997-04-04	2000-05-16	Merck & Co., Inc.	Somatostatin agonists

1998
- 1998-11-16 US US09/192,406 patent/US6124263A/en not_active Expired - Fee Related
1999
- 1999-10-28 CO CO99068206A patent/CO5140111A1/es unknown
- 1999-11-11 DK DK99955974T patent/DK1131083T3/da active
- 1999-11-11 BR BR9915390-4A patent/BR9915390A/pt not_active IP Right Cessation
- 1999-11-11 CA CA002350914A patent/CA2350914A1/en not_active Abandoned
- 1999-11-11 TR TR2001/01350T patent/TR200101350T2/xx unknown
- 1999-11-11 AT AT99955974T patent/ATE258062T1/de not_active IP Right Cessation
- 1999-11-11 PL PL99347659A patent/PL347659A1/xx unknown
- 1999-11-11 CZ CZ20011577A patent/CZ20011577A3/cs unknown
- 1999-11-11 CN CNB998133612A patent/CN1200726C/zh not_active Expired - Fee Related
- 1999-11-11 DE DE69914365T patent/DE69914365T2/de not_active Expired - Fee Related
- 1999-11-11 CN CNB2006100998244A patent/CN100368014C/zh not_active Expired - Fee Related
- 1999-11-11 KR KR1020017006163A patent/KR100704138B1/ko not_active Expired - Fee Related
- 1999-11-11 HK HK02102769.3A patent/HK1040934A1/zh unknown
- 1999-11-11 PT PT99955974T patent/PT1131083E/pt unknown
- 1999-11-11 RU RU2001116722/14A patent/RU2240133C2/ru not_active IP Right Cessation
- 1999-11-11 NZ NZ511280A patent/NZ511280A/xx unknown
- 1999-11-11 ES ES99955974T patent/ES2212650T3/es not_active Expired - Lifetime
- 1999-11-11 UA UA2001064044A patent/UA73100C2/uk unknown
- 1999-11-11 SK SK635-2001A patent/SK6352001A3/sk unknown
- 1999-11-11 MX MXPA01004689A patent/MXPA01004689A/es not_active IP Right Cessation
- 1999-11-11 IL IL14285899A patent/IL142858A0/xx unknown
- 1999-11-11 HU HU0104374A patent/HUP0104374A3/hu unknown
- 1999-11-11 EP EP99955974A patent/EP1131083B1/de not_active Expired - Lifetime
- 1999-11-11 JP JP2000582057A patent/JP2002529512A/ja active Pending
- 1999-11-11 CN CNB200410045995XA patent/CN1277840C/zh not_active Expired - Fee Related
- 1999-11-11 WO PCT/EP1999/008662 patent/WO2000029011A1/en not_active Ceased
- 1999-11-16 AR ARP990105814A patent/AR021286A1/es unknown
- 1999-11-30 TW TW088117984A patent/TWI237565B/zh not_active IP Right Cessation
- 1999-11-30 TW TW094111886A patent/TWI263642B/zh not_active IP Right Cessation
2001
- 2001-04-19 ZA ZA200103182A patent/ZA200103182B/en unknown
- 2001-05-14 NO NO20012367A patent/NO20012367L/no not_active Application Discontinuation
- 2001-06-07 BG BG105572A patent/BG105572A/xx unknown

Also Published As

Publication number	Publication date
WO2000029011A1 (en)	2000-05-25
DE69914365T2 (de)	2004-11-04
KR100704138B1 (ko)	2007-04-09
TR200101350T2 (tr)	2001-11-21
CN1895660A (zh)	2007-01-17
HK1040934A1 (zh)	2002-06-28
CA2350914A1 (en)	2000-05-25
HUP0104374A3 (en)	2003-03-28
TWI237565B (en)	2005-08-11
SK6352001A3 (en)	2002-09-10
AR021286A1 (es)	2002-07-03
TW200530270A (en)	2005-09-16
IL142858A0 (en)	2002-03-10
CZ20011577A3 (cs)	2002-07-17
JP2002529512A (ja)	2002-09-10
ZA200103182B (en)	2001-09-07
CN1277840C (zh)	2006-10-04
KR20010089459A (ko)	2001-10-06
ES2212650T3 (es)	2004-07-16
BR9915390A (pt)	2001-08-07
CN1200726C (zh)	2005-05-11
CO5140111A1 (es)	2002-03-22
PT1131083E (pt)	2004-06-30
BG105572A (en)	2002-01-31
TWI263642B (en)	2006-10-11
CN100368014C (zh)	2008-02-13
HUP0104374A2 (hu)	2002-04-29
PL347659A1 (en)	2002-04-22
DK1131083T3 (da)	2004-04-26
NO20012367D0 (no)	2001-05-14
RU2240133C2 (ru)	2004-11-20
ATE258062T1 (de)	2004-02-15
DE69914365D1 (de)	2004-02-26
CN1326353A (zh)	2001-12-12
EP1131083A1 (de)	2001-09-12
US6124263A (en)	2000-09-26
MXPA01004689A (es)	2002-09-18
NZ511280A (en)	2002-10-25
NO20012367L (no)	2001-07-09
EP1131083B1 (de)	2004-01-21
CN1594358A (zh)	2005-03-16

Publication	Publication Date	Title
UA73100C2 (en)	2005-06-15	Method for inhibiting proliferation of cancer cells by administering growth hormone releasing compound or its antagonist
US8377865B2 (en)	2013-02-19	Growth hormone releasing peptides
US8524668B2 (en)	2013-09-03	Methods of protecting against apoptosis using lipopeptides
EP0644772B1 (de)	2003-04-02	Opioidpeptide
US20100168038A1 (en)	2010-07-01	Use of compounds in combination with gamma-irradiation for the treatment of cancer
TW575582B (en)	2004-02-11	Somatostatin antagonists
Tsutsumi et al.	1993	Biphasic effects of suramin on125I-epidermal growth factor binding to human meningiomas
US12024515B2 (en)	2024-07-02	Kifunensine derivatives
AU1270600A (en)	2000-06-05	Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
Bowers	2000	GHRP historical perspective: basic and clinical
AU2007202409B2 (en)	2009-01-29	Growth hormone releasing peptides
Pleasanton et al.	0	Aurrecoechea et al.(43) Pub. Date: Jul. 20, 2006
Glavaski	2003	Stimulatory effect of endogenous and exogenous growth hormone secretagogues on isolated porcine somatotropes